The Research Pharmacy Shared Service (RPSS) is one of the founding core services for this Cancer Center Support grant. It is responsible for investigation cancer drug inventory and preparation for the Multi- disciplinary Clinics of the Arizona Cancer Center. Located in the clinic area of the first floor, the service prepares over 2,800 investigation agents yearly, facilitated through the funding of a pharmacy technician, Estelle Wesau. Robert Dorr, Ph.D., R.Ph. is funded at 10% and serves as director of the services. He oversees the technician and investigational drug logistics for the entire Center. In addition, Dr. Dorr also prepares samples of investigation topical of injectable formulations of new agents or repackages active and placebo dosages for double-blinded pilot clinical trials. The later service totaled six projects for drug formulation and three projects for double-blind repackaging, respectively. The repackaged investigational agents are primarily used in the Cancer Prevention and Control Research Program. The Research Pharmacy Shared Service provides investigational drug reconstitution for daily clinics in the Cancer Center and as such, swerves a variety of peer-reviewed clinical projects including those of the Southwest Oncology Group (SWOG) and the clinical trials of three large translational research program project grants: the Medical Oncology Program Project, the Colon Cancer Prevention Program Project, and the Chemoprevention of Skin Cancer Program Project. Private (drug company) or other investigational trials may use the service of a when-available charge-back basis with funds used to buy equipment (freezers, computer, infusion pumps, etc.) to enhance the overall service effort. However, federal funding for this service is crucial since there are no charges to patients for preparation of any investigational drug, as it is done to pay for pharmacy services with commercially-available drugs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA023074-22
Application #
6101952
Study Section
Project Start
1999-07-01
Project End
2000-06-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
22
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Arizona
Department
Type
DUNS #
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Lent, Adrienne B; O'Connor, Patrick A; Reikowsky, Ryan C et al. (2018) Quit outcomes among clients ineligible for cessation medication through the state quitline: a retrospective, observational study. BMC Public Health 18:1001
Bea, J W; Hsu, C-H; Blew, R M et al. (2018) Use of iDXA spine scans to evaluate total and visceral abdominal fat. Am J Hum Biol 30:
Bulkley, Joanna E; McMullen, Carmit K; Grant, Marcia et al. (2018) Ongoing ostomy self-care challenges of long-term rectal cancer survivors. Support Care Cancer 26:3933-3939
Zaim, Samir Rachid; Li, Qike; Schissler, A Grant et al. (2018) Emergence of pathway-level composite biomarkers from converging gene set signals of heterogeneous transcriptomic responses. Pac Symp Biocomput 23:484-495
Kobes, Joseph E; Georgiev, George I; Louis, Anthony V et al. (2018) A Comparison of Iron Oxide Particles and Silica Particles for Tracking Organ Recellularization. Mol Imaging 17:1536012118787322
Kelly, K R; Espitia, C M; Zhao, W et al. (2018) Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy. Leukemia 32:230-233
Downs, Charles A; Johnson, Nicholle M; Tsaprailis, George et al. (2018) RAGE-induced changes in the proteome of alveolar epithelial cells. J Proteomics 177:11-20
Sun, Virginia; Wendel, Christopher S; Demark-Wahnefried, Wendy et al. (2018) Diet and Behavior Modifications by Long-term Rectal Cancer Survivors to Manage Bowel Dysfunction-Associated Symptoms. Nutr Cancer :1-11
Mushtaq, Adeela; Kapoor, Vikas; Latif, Azka et al. (2018) Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review. Crit Rev Oncol Hematol 125:1-11
Rak, Michael A; Buehler, Jason; Zeltzer, Sebastian et al. (2018) Human Cytomegalovirus UL135 Interacts with Host Adaptor Proteins To Regulate Epidermal Growth Factor Receptor and Reactivation from Latency. J Virol 92:

Showing the most recent 10 out of 1336 publications